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Dr Wilson Szeto (Philadelphia, Pa). Tom, fantastic presenta-
tion, well-written manuscript. Thank you in advance for sending
the manuscript to us for review. You and your colleagues at Emory
should be congratulated on such a well-timed study. As you know,
for patients with severe renal impairment, there is really not a
whole lot of data regarding the role of TAVR in this patient popula-
tion. As you know, that is an exclusion for the PARTNER trial.
You have nicely demonstrated that, in this population in a center
of excellence, mortality can be kept at 4.4% despite their signifi-
cant comorbidities. So, I congratulate you on that.
A few comments in terms of the data and I will follow up with 3
questions. First, I would reconsider your conclusion that TAVR
mitigates the long-term effect of severe renal dysfunction on
survival outcome. In your survival curve in the severe renal
impairment group undergoing TAVR, there were I think 3 patients
at 1-year follow-up. I would caution as calling that long-term
outcome and survival improvement.
Number 2, as you so elegantly displayed on your preoperative
demographic slides, these clearly are 2 separate sets of patients:
the surgical patients and the TAVR patients were different. In
your manuscript, you share that the 4-year survival in the surgical
group was 82.4% versus 26% in the TAVR group. So, clearly,
again, this emphasizes that these are different cohorts.
But, let’s focus on why we are interested in this abstract, which
is the role of TAVR in patients with severe renal dysfunction. So, 3
questions. I will ask them in sequence, and I will give you a chance
to answer.
The first one. Just out of curiosity, what was the percentage or
the ratio of TF versus transapical and direct aortic? And, as you
know, this is not so much a reflection of technique but also a
reflection of patient comorbidities. Can you comment on that in
terms of your experience in the TAVR group?1406 The Journal of Thoracic and Cardiovascular SurDr Nguyen. Thank you, Dr Szeto, for your thoughtful and
constructive comments of the presentation and the manuscript.
Of our patients, 60% were transfemoral, 30% were transapical,
and the rest were transaortic. When we looked at access as a mea-
sure of outcome, we found that both transfemoral and transapical
access increased postoperative GFR of near-equal magnitude. We
did not appreciate this increase with the transaortic subgroup.
Dr Szeto. Second question. Looking specifically at patients
with severe renal impairment, because that is really the group
we are interested in because this is the set of patients that we do
not have a whole lot of data on, you stated in your manuscript
that development of new postoperative renal failure was signifi-
cantly higher in surgical AVR patients. At the same time, the
preoperative baseline creatinine was also higher in that group.
So, the saying goes, not all renal impairment patients are the
same. Can you further elaborate on the specific characteristics of
their renal impairment?What was the breakdown between patients
with severe renal impairment but not on dialysis versus the patients
on dialysis? And for patients on dialysis, how long had they been
on dialysis?
Dr Nguyen. That is a great question. Unfortunately, the data
were queried from the STS database, so we do not have informa-
tion on the duration of hemodialysis. We do know that, in our
SAVR subgroup, roughly 60% were on hemodialysis, and interest-
ingly enough, the death rate for our SAVR group on hemodialysis
was 14%.
Looking at our TAVR subgroup, approximately 34% were on
hemodialysis, and our death rate was 0%.
Dr Szeto. And, the last question is sort of a bigger picture
patient selection question. Your group has shown that we can do
this safely in a 30-day period with a 4.4% mortality, even in
patients with severe renal insufficiency. As you know, over the
last 4 years, we have struggled with the question of futility versus
utility. There are patients, as you know, that are so sick and
considered futile for TAVR, the so-called cohort Cs. Based on
your data, what can you share with the rest of us in terms of
recommendations for patient selection when someone comes in
your clinic who has aortic stenosis whom you think are either
high risk or inoperable and have severe renal insufficiency or
dialysis? Should we be treating these patients with TAVR or
not? Other groups, such as the Dallas group, have had disap-
pointing early data, and they have stopped doing so. I would like
to thank the Association for the privilege to discuss this paper.
DrNguyen.Your last comment is really the million dollar ques-
tion, specifically, what do we do with patients with end-stage renal
disease with severe aortic stenosis? At Emory, we treat each of
these patients on a case-by-case basis. So, for the young ESRD pa-
tient with a relatively low STS score and minimal comorbidities,
then we will approach TAVR with relatively low reluctance. On
the other hand, our research and other publications suggested
that patients with severe COPD and end-stage renal disease are
those patients that we tend to shy away from. But, for the most
part, we do try to approach these patients on a case-by-case basis,
and we do not necessarily exclude just because they have end-stage
renal disease or are on hemodialysis.
Dr Szeto. How about newly placed on hemodialysis versus
being on it for 5 to 8 years, is that also a screening tool for you
as well, the duration of time they have been on hemodialysis?gery c December 2013
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variable to consider, and we are more aggressive if a patient has
only recently been on hemodialysis.
DrHarold Lazar (Boston, Mass). As we all know, themortality
and the long-term survival for patients with chronic renal failure
on dialysis who receive a valve replacement, their 3-year survival
has been reported to be as low as 25%, and a lot of people think that
maybe TAVRmight be a good indication for that. Do you have any
long-term data, though, as far as the durability of these valves? Do
these valves last that long in patients who have chronic renal fail-
ure on dialysis, are they more prone to calcification, do they have
higher gradients?
Dr Nguyen. Unfortunately, the valves are tissue valves, and, in
theory, we assume that they will last just as long as our
bioprosthetic valves, roughly 10 to 15 years, but the reality is we
do not know. The PARTNER trial started in 2007, and we do not
have long-term data.
DrRalph Damiano (St Louis, Mo). I have a couple of questions
for you. First of all, did you look at the timing of the preoperative
cardiac catheterization in the 2 groups and whether that may have
influenced the incidence of renal insufficiency, particularly in
those that had progression of renal dysfunction? Certainly, the
UVA group has shown that if you perform the catheterization right
before the surgery, it is associated with worsening renal function as
opposed to doing it at some distance prior to surgery. At least I
know in our institution for valve procedures, they tend to come
in the day before and get a catheterization and then go right to
surgery. For our transcatheter valves, the catheter is often done
weeks before surgery. Have you looked at the timing of the cardiac
catheterization as a variable that may have predicted worse
outcome in patients, particularly who had an elevated creatinine
but have not yet gone on dialysis?
Dr Nguyen. As you alluded to, the TAVR workup is fairly
comprehensive and most of the patients have their workup
completed weeks prior to valve implantation. So, it is rare that
we will catheterize the patient the day prior to surgery. So, by
the time they are getting the TAVR, the potential nephrotoxic
effects of the contrast have subsided. There have been other studies
that have clumped these patient cohorts with a left heart
catheterization and then the TAVR, and they also appreciate a
slight increase in GFR postoperatively.The Journal of Thoracic and CarThe interesting point from a more philosophical stand point is
for the kidneys, what is really worse, is it the cardiopulmonary
bypass or is it the contrast load? And, our data seem to suggest
that the contrast load is less deleterious than the cardiopulmonary
bypass run. And, if you think about it also, the contrast that we
used was roughly around 150 mL. When we do a CT angiogram
of the chest, abdomen and pelvis, that is about 150 mL. So, if
you are doing a CT angiogram on a patient, it is roughly about
the same amount of contrast that we use for our TAVR patients.
We do try to be judicious about the contrast load for the patients
with severe renal dysfunction, and our average contrast load for
these patients is roughly 70 to 80 mL.
Dr Damiano. I will ask my question again. You compared the 2
groups, surgical versus transcatheter, and my question is, was the
timing of the cardiac catheterization different in those 2 groups,
because at least in our institution it is, and would that have
influenced at all your results?
Dr Nguyen. This study was not designed as a superiority study.
It was designed as an intergroup comparison looking at trends
within the surgical AVR and within the TAVR group. To
actually compare the 2 groups, the best approach would be a
propensity-matched analysis in which we do not have a large
enough patient population, although this is the largest series
known to date looking at TAVR patients with varying degrees of
renal dysfunction.
DrDamiano.And, then, one quick last question.Youmentioned
that in the dialysis patients that you had much higher mortality in
the surgical than in the transcatheter group, because you said in
patients on dialysis there were no deaths. Admittedly, it is a small
group.
Dr Nguyen. Correct.
Dr Damiano. What was the cause of death in these dialysis
patients and did that differ between the 2 groups? When you are
talking about the potential mortality benefit of transcatheter valve
replacement in these patients with end-stage renal disease, where
is that benefit? Is this early or late death, was the cause of death
somehow related to progression of renal dysfunction, or was this
all-cause mortality? I want to get some feeling for when did the
patients die and what was the cause of death?
Dr Nguyen. For those specific end-stage renal disease patients
on hemodialysis, we looked at short-term mortality.diovascular Surgery c Volume 146, Number 6 1407
